Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of HPV-negative head and neck squamous cell carcinoma
Humanistic burden and health-related quality of life
6 evidence topics · 6 sources
KEYNOTE-048 health-related quality of life instruments and endpoints
“HRQoL was measured using the European Organisation for Research and Treatment of Cancer 30-question quality-of-life (EORTC QLQ-C30), the EORTC 35-question quality-of-life head and neck cancer-specific module (EORTC QLQ-H&N35), and the EuroQol 5-dimension 3-level instruments (EQ-5D-3L).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Secondary endpoints included mean change from baseline in EORTC QLQ-C30 global health status/quality of life (GHS/QoL) at week 15 and time to deterioration (TTD) in EORTC QLQ-C30 GHS/QoL and EORTC QLQ-H&N35 pain and swallowing.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
KEYNOTE-048 global health status at week 15 and time to deterioration
“Of 882 enrolled participants, 844 received ≥ 1 dose of study treatment and completed ≥ 1 HRQoL assessment; adherence was ≥ 79% at week 15 across treatment groups.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At week 15, EORTC QLQ-C30 GHS/QoL scores remained stable; no clinically meaningful between-group differences were observed (least squares mean difference, pembrolizumab vs cetuximab-chemotherapy, 0.24; 95% CI, -3.34 to 3.82; pembrolizumab-chemotherapy vs cetuximab-chemotherapy, 0.40; 95% CI, -3.46 to 4.26).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median TTD in EORTC QLQ-C30 GHS/QoL and EORTC QLQ-H&N35 pain and swallowing scores was not reached over 51 weeks across groups, showing stable HRQoL.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“TTD was similar between groups for EORTC QLQ-C30 GHS/QoL (pembrolizumab vs cetuximab-chemotherapy: HR, 1.38; 95% CI, 0.95-2.00; pembrolizumab-chemotherapy vs cetuximab-chemotherapy: HR, 1.37; 95% CI, 0.94-2.00), as was TTD in EORTC QLQ-H&N35 pain and swallowing scores.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Real-world quality of life during pembrolizumab treatment
“We retrospectively analyzed the data of patients with recurrent or metastatic head and neck cancer who underwent pembrolizumab treatment at our institution between 2020 and 2023.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In total, 68 patients were included in the analysis. The mean GHS score increased from 57.0 at baseline to 62.5 at nine weeks, indicating a trend toward improvement (p=0.051). The GHS score remained higher at 18 weeks (58.7) than at baseline, although the difference was not statistically significant.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Health-state utility values in head and neck cancer
“Of a total 1048 records identified by the search, 28 studies qualified for data extraction and 346 unique HSUVs were retrieved from them.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There is currently a lack of research for some disease phases including recurrent and metastatic cancer, and treatment-related complications.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Utilities used in US cost-effectiveness models of first-line treatment
Time spent on care during immune checkpoint inhibitor treatment
“Of 56 patients evaluated, median age was 63 years (33–85) and 84% were male. Median overall survival (OS) and grade 3 immune-toxicities were 7.6 months and 6.2%, respectively. Median TT was 24 days (1–109), accounting for 7.6% of OS. TT accounted for 14.9% of OS in poor responders.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote